The Company

BioDynLab has been co-founded by Jacek Marczyk and Shrutya Bhalla in early 2026 and is headquartered in Toronto, Canada.

We are a deep-tech company focusing on novel, physics-based innovation in accelerating drug discovery. Our mission is to advance human health by generating new scientific knowledge that drives breakthroughs in life sciences R&D.

The underlying technology powering BioDynLab's research and products is the Quantitative Complexity Theory (QCT), which has been tested and applied in numerous fields, including medicine, manufacturing and finance.

The QCT coupled with Molecular Dynamics, allows to establish the first Dynamic Molecular Complexity (DMC) metric for small molecules, peptides and proteins, providing new insights into their intricate dynamics. Our product offering comprises OPTIMUS™ and MACRO™, physics-based Molecular Complexity Analysis platforms for small molecules and peptides/proteins.

We understand that at atomic level all biological systems are characterized by highly complex structural interactions and non-linear dynamics. The DMC, which bridges physics and information theory, establishes quantitative methodologies towards the understanding of these interactions and of the resulting relationship between dynamics, structure, and biological function. From atoms to biology.

BioDynLab’s technology is training-free and offers full explainability, beyond mainstream AI techniques.